Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) reduces the quality of life, costs substantial medical resources, and has a high mortality. However, we lack an effective therapy for HFpEF due to our limited knowledge of its mechanism. Therefore, it is crucial to explore novel therapeutics, such as those with endogenous protective roles, and seek new targeted therapies. Epoxyeicosatrienoic acids (EETs) are endogenous bioactive metabolites of arachidonic acids produced by cytochrome P450 (CYP) epoxygenases. EETs can function as endogenous cardioprotective factors with potent inhibitory roles in inflammation, endothelial dysfunction, cardiac remodeling, and fibrosis, which are the fundamental mechanisms of HFpEF. This suggests that EETs have the potential function to protect against HFpEF. Therefore, we present an overview of the ever-expanding world of EETs and how they might help alleviate the pathophysiology underlying HFpEF to provide new insights for research in this field.

Automated summary

Heart failure with preserved ejection fraction (HFpEF) has a negative impact on quality of life, requires significant medical resources, and has a high mortality rate. Currently, there is a lack of effective therapy for HFpEF due to limited knowledge of its mechanism. Epoxyeicosatrienoic acids (EETs) are endogenous cardioprotective factors that have inhibitory effects on the fundamental mechanisms of HFpEF, such as inflammation, endothelial dysfunction, cardiac remodeling, and fibrosis. Therefore, exploring the potential of EETs as a therapeutic target for HFpEF is crucial.